BRD4 and acute lymphoblastic leukemia: In order to choose primary B-ALL patient samples for further analysis, we made selections based on their diagnosis status (relapsed or refractory), expression of both PI3Kδ (Figure S1A) and BRD4 (Figure S1B) based on quantitative densitometric analysis, and inclusion of a wide range of karyotypes including BCR-ABL1+ status.